arsenic has been researched along with darinaparsin in 30 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 10 (33.33) | 29.6817 |
2010's | 16 (53.33) | 24.3611 |
2020's | 4 (13.33) | 2.80 |
Authors | Studies |
---|---|
Hirano, S; Kobayashi, Y | 1 |
Himeno, S; Hirano, S; Kobayashi, Y; Kojima, C; Sakurai, MH; Sakurai, T; Waalkes, MP | 1 |
Feldmann, J; Jaspars, M; Meharg, AA; Raab, A; Wright, SH | 1 |
Colombo, M; Diaz, Z; Komarnitsky, PB; Kourelis, M; Mann, KK; Marcoux, S; Miller, WH | 1 |
Kanaki, K; Pergantis, SA | 1 |
Chen, YW; Freireich, E; Kantarjian, H; Quintás-Cardama, A; Verstovsek, S; Zingaro, R | 1 |
Aguirre, V; Arriagada, S; Bertoglio, JC; Burgos, RA; Cáceres, DD; Calvo, M; Hancke, JL | 1 |
Boise, LH; Cai, Y; Croutch, C; Gutman, D; Lee, KP; Matulis, SM; Morales, AA; Yehiayan, L | 1 |
Abbadessa, G; Blaszkowsky, LS; Chen, H; Costa, M; Feun, L; Gold, P; Henderson, C; Hochster, H; Lewis, J; Muggia, F; Nierodzik, M; Rosenzweig, B; Ryan, T; Van Veldhuizen, P; Wu, J; Zheng, H; Zhu, AX | 1 |
Camacho, LH; Daring, S; Gutierrez, C; Hong, DS; Komarnitsky, PB; Kurzrock, R; Ng, C; Schwartz, B; Stevens, J; Tsimberidou, AM; Uehara, CK; Verstovsek, S | 1 |
Lossos, IS; Mann, KK; Miller, WH; Wallner, B | 1 |
Boccia, RV; Craig, MD; Hamilton, BL; Hosein, PJ; Lewis, JJ; Lossos, IS; Tallman, MS | 1 |
Chiang, C; Goldenring, JR; Kolobova, E; Liu, J; Mason, TA; Roland, JT | 1 |
Knox, SJ; Li, X; Nolley, R; Peehl, DM; Reese, SW; Tian, J; Young, SR; Zhao, H | 1 |
del Rincon, SV; Diaz, Z; Garnier, N; Gupta, A; Kourelis, M; Kwan, S; Mann, KK; Miller, WH; Molina, MF; Petruccelli, LA; Schipper, HM | 1 |
Doi, H; Knox, SJ; Li, X; Peehl, DM; Saar, M; Santos, J; Tian, J | 1 |
Bohle, DS; Conklin, DS; Dahabieh, MS; del Rincon, SV; Garnier, N; Gu, Y; Mann, KK; Miller, WH; Nichol, JN; Redstone, GG; Sun, Y | 1 |
Boise, LH; Cai, Y; Liu, G; Matulis, S; Stice, S; Yehiayan, L | 1 |
Bhalla, S; Crombie, J; Evens, AM; Gartenhaus, RB; Kandela, I; Mazar, A; Ravi, D; Sharma, J | 1 |
Bansal, N; Bertino, JR; Farley, NJ; Lewis, J; Wu, L; Youssoufian, H | 1 |
Chang, SL; DiRocco, DP; Fabian, SL; Fleig, SV; Heckl, D; Humphreys, BD; Ikeda, Y; Kramann, R; Maarouf, O; Rennke, HG; Schneider, RK; Waikar, SS; Wongboonsin, J | 1 |
Boise, LH; Cai, Y; Liu, G; Matulis, S; Stice, S | 1 |
Hirano, S; Kato, A; Kobayashi, Y; Udagawa, O | 1 |
Cai, Y; McCord, B; McGoron, AJ; Mebel, A; Sun, Y; Yang, M; Zhang, X | 1 |
Bae, H; Ito, I; Kubota, K; Nagahama, F; Okamoto, T; Sonehara, Y; Tateishi, U; Tsuchiya, J | 1 |
Guan, X; Hu, X; Li, H; Sun, H; Toy, PH; Wang, H; Xu, X; Zhang, Y | 1 |
Chowdhury, T; Mandal, SM; Roymahapatra, G | 1 |
Ishizawa, K; Kim, WS; Nagahama, F; Nagai, H; Ogura, M; Sonehara, Y; Suehiro, Y; Tobinai, K; Uchida, T; Uike, N | 1 |
Ando, K; Fukuhara, N; Izutsu, K; Kang, HJ; Kim, WS; Ko, PS; Kwong, YL; Nagahama, F; Nagai, H; Nakajima, H; Negoro, E; Sonehara, Y; Suehiro, Y; Terui, Y; Tien, HF; Tobinai, K; Uchida, T; Yamamoto, K; Yoon, DH | 1 |
Nagahama, F; Sonehara, Y; Yao, K | 1 |
1 review(s) available for arsenic and darinaparsin
Article | Year |
---|---|
Darinaparsin: a novel organic arsenical with promising anticancer activity.
Topics: Animals; Antineoplastic Agents; Arsenicals; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Glutathione; Humans; Neoplasms; Signal Transduction | 2009 |
8 trial(s) available for arsenic and darinaparsin
Article | Year |
---|---|
Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Andrographis; Arsenicals; Arthralgia; Arthritis, Rheumatoid; Chloroquine; Double-Blind Method; Drug Therapy, Combination; Female; Glutathione; Humans; Methotrexate; Middle Aged; Phytotherapy; Placebos; Plant Extracts; Plant Leaves; Prednisone; Prospective Studies; Radiography; Severity of Illness Index; Young Adult | 2009 |
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenicals; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Glutathione; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2010 |
A phase I clinical trial of darinaparsin in patients with refractory solid tumors.
Topics: Area Under Curve; Arsenicals; Ataxia; Dizziness; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Glutathione; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Nervous System Diseases; Treatment Outcome | 2009 |
A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Arsenicals; Female; Glutathione; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Treatment Outcome | 2012 |
Standardization of [F-18]FDG PET/CT for response evaluation by the Radiologic Society of North America-Quantitative Imaging Biomarker Alliance (RSNA-QIBA) profile: preliminary results from the Japan-QIBA (J-QIBA) activities for Asian international multice
Topics: Aged; Arsenicals; Asia; Biomarkers; Female; Fluorodeoxyglucose F18; Glutathione; Humans; Internationality; Japan; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; North America; Phantoms, Imaging; Positron Emission Tomography Computed Tomography; Radiology; Radiopharmaceuticals; Reference Standards; Societies, Medical; Treatment Outcome | 2018 |
Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea.
Topics: Adult; Aged; Aged, 80 and over; Arsenicals; Female; Glutathione; Humans; Japan; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Republic of Korea; Time Factors; Treatment Outcome; Young Adult | 2021 |
Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study.
Topics: Arsenicals; Glutathione; Humans; Lymphoma, T-Cell, Peripheral; Neutropenia | 2023 |
[Pharmacological profile and clinical study results of darinaparsin (DARVIAS
Topics: Arsenic; Arsenicals; Cystine; Glutathione; Humans; Lymphoma, T-Cell, Peripheral | 2023 |
21 other study(ies) available for arsenic and darinaparsin
Article | Year |
---|---|
Cytotoxic effects of S-(dimethylarsino)-glutathione: a putative intermediate metabolite of inorganic arsenicals.
Topics: Animals; Arsenicals; Arsenites; Cell Culture Techniques; Cell Survival; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Endothelial Cells; Gas Chromatography-Mass Spectrometry; Glutathione; HL-60 Cells; Humans; Rats; Sodium Compounds | 2006 |
Toxicity of a trivalent organic arsenic compound, dimethylarsinous glutathione in a rat liver cell line (TRL 1215).
Topics: Animals; Antineoplastic Agents; Arsenic Poisoning; Arsenicals; Arsenites; Cacodylic Acid; Cell Line; Cell Survival; Chromatography, Thin Layer; Dose-Response Relationship, Drug; Erythrocytes; Glutathione; Hepatocytes; Humans; Inhibitory Concentration 50; Methylation; Rats; Rats, Inbred F344; Serum Albumin; Time Factors | 2006 |
Pentavalent arsenic can bind to biomolecules.
Topics: Arsenic; Arsenicals; Binding Sites; Biopolymers; Brassica; Chromatography, High Pressure Liquid; Glutathione; Mass Spectrometry; Peptides; Sulfur | 2007 |
A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutathione; Hematologic Neoplasms; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mice; Multidrug Resistance-Associated Proteins; Oncogene Proteins, Fusion; Oxidative Stress; Oxides | 2008 |
Development of mass spectrometric methods for detecting arsenic-glutathione complexes.
Topics: Arsenicals; Arsenites; Cacodylic Acid; Chromatography, High Pressure Liquid; Glutathione; Sodium Compounds; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2008 |
Chemical and clinical development of darinaparsin, a novel organic arsenic derivative.
Topics: Animals; Antineoplastic Agents; Arsenicals; Drug Screening Assays, Antitumor; Glutathione; Humans; Leukemia, Myeloid, Acute; Mice | 2008 |
Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cysteine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Multiple Myeloma; Oxides | 2009 |
Darinaparsin is a multivalent chemotherapeutic which induces incomplete stress response with disruption of microtubules and Shh signaling.
Topics: Animals; Antineoplastic Agents; Arsenicals; Arsenites; Cilia; Glutathione; Hedgehog Proteins; HeLa Cells; Humans; Mice; Microtubules; NIH 3T3 Cells; Polymerization; Signal Transduction; Sodium Compounds; Stress, Physiological | 2011 |
Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Hypoxia; Glutathione; Humans; Intestines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oxides; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Radiation-Sensitizing Agents; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2012 |
The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blast Crisis; Blotting, Western; Cell Cycle; Cell Proliferation; Chromatin Immunoprecipitation; Cytoprotection; DNA Helicases; Flow Cytometry; Glutathione; Heme Oxygenase-1; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Nuclear Proteins; Oxides; Phosphorylation; Promoter Regions, Genetic; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured | 2013 |
Radioprotection and cell cycle arrest of intestinal epithelial cells by darinaparsin, a tumor radiosensitizer.
Topics: Animals; Apoptosis; Arsenicals; Cell Cycle Checkpoints; DNA Damage; DNA Repair; Duodenum; Epithelial Cells; Female; Gastrointestinal Tract; Glutathione; Heterografts; Humans; Male; Mice; Prostatic Neoplasms; Radiation Injuries, Experimental; Radiation Tolerance; Radiation-Protective Agents; Radiation-Sensitizing Agents; Syndrome | 2013 |
The novel arsenical darinaparsin is transported by cystine importing systems.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biological Transport; Cell Line, Tumor; Cysteine; gamma-Glutamyltransferase; Glutathione; Humans; Oxides; Sulfhydryl Compounds | 2014 |
Dimethylarsinothioyl glutathione as a metabolite in human multiple myeloma cell lines upon exposure to Darinaparsin.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Line, Tumor; Glutathione; Humans; Multiple Myeloma | 2014 |
The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.
Topics: Animals; Apoptosis; Arsenic; Arsenicals; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Glutathione; Hodgkin Disease; Humans; Intracellular Space; Lymphoma, T-Cell; Mice; Mitogen-Activated Protein Kinases; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signaling.
Topics: Animals; Antineoplastic Agents; Arsenicals; Cell Cycle; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glutathione; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Male; Mice; Neoplastic Stem Cells; Nuclear Proteins; Prostatic Neoplasms; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays; Zinc Finger Protein Gli2 | 2015 |
Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis.
Topics: Animals; Arsenicals; Cell Cycle Checkpoints; Cell Line; Fibrosis; Glutathione; Humans; Kidney; Kidney Diseases; Kruppel-Like Transcription Factors; Mice; Mice, Knockout; Myofibroblasts; Pyridines; Pyrimidines; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2015 |
Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometry.
Topics: Arsenicals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Glutathione; Humans; Limit of Detection; Mass Spectrometry; Neoplasms; Sulfur | 2016 |
Pharmacodynamics of S-dimethylarsino-glutathione, a putative metabolic intermediate of inorganic arsenic, in mice.
Topics: Animals; Antineoplastic Agents; Arsenicals; Arsenites; Glutathione; Injections, Intravenous; Male; Mice, Inbred C57BL; Protein Binding; Serum Albumin; Sodium Compounds; Tissue Distribution | 2017 |
Raman spectra of thiolated arsenicals with biological importance.
Topics: Arsenicals; Cacodylic Acid; Glutathione; Organometallic Compounds; Quantum Theory; Solutions; Spectrum Analysis, Raman; Vibration; Water | 2018 |
S-Dimethylarsino-glutathione (darinaparsin®) targets histone H3.3, leading to TRAIL-induced apoptosis in leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Glutathione; Histones; Humans; Leukemia, Promyelocytic, Acute; Molecular Structure; TNF-Related Apoptosis-Inducing Ligand | 2019 |
In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases.
Topics: Antiviral Agents; Arsenicals; Computer Simulation; COVID-19; Glutathione; Humans; Molecular Docking Simulation; Peptide Hydrolases; Protease Inhibitors; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2021 |